Novacyt SA (ALNOV):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Novacyt SA (ALNOV) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7913
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:82
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Novacyt SA (Novacyt) is a medical device company that develops and markets medical cytology solutions. The company offers oncology and infectious disease diagnostic products. It also sells diagnostic reagents used in LBC, oncology, microbiology, haematology and serology testing. Novacyt develops proprietary technology platform NOVAPREP, a next generation liquid based cytology solution focused on cancer management. The company’s cytology solution is also used in medical laboratories for diagnoses of diseases based on the study of organs and tissues on a molecular level. It has operations in France and the UK. Novacyt is headquartered in Paris, France.

Novacyt SA (ALNOV) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Novacyt SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Novacyt SA, Medical Equipment Deals By Type, 2012 to YTD 2018 8
Novacyt SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Novacyt SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 10
Novacyt SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
Novacyt SA, Medical Equipment, Deal Details 13
Asset Purchase 13
Lab21 Healthcare to Acquire Infectious Disease Business from Omega Diagnostics for up to USD2.8 Million 13
Novacyt Acquires Assets Of Centre de Competences International en Tele-Imagerie 14
Venture Financing 15
Lab21 Raises US$7.7 Million In Venture Financing 15
Novacyt Raises US$2 Million In Venture Financing 16
Private Equity 17
Selah Genomics Acquires Lab21, Maker Of Nanotechnology-Enabled Products 17
Partnerships 18
Lab21 Enters Into Licensing Agreement With Cooperative Diagnostics 18
PrimerDesign Partners with Applied Microarrays 19
Novacyt Enters into Partnership with Cepheid 20
Novacyt Enters into Clinical Trial Agreement with St Stephen’s AIDS Trust 21
Lab21 Enters Into Agreement With IntegraGen To Develop Cancer Diagnostic 22
BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 23
Lab21 Enters Into Co-Development Agreement With Pharma Company 24
LAB21 Enters Into Co-Development Agreement With IVD Company For Aspergillus Molecular Assay 25
Equity Offering 26
Novacyt Raises USD11.4 Million in Private Placement of Shares 26
Novacyt Raises USD3.35 Million in Public Offering of Shares 27
Novacyt Raises USD0.2 Million in Public Offering of Shares 28
Novacyt Raises USD2.9 Million in Public Offering of Shares 29
Novacyt Raises USD0.1 Million in Public Offering of Shares 30
Novacyt Raises USD0.1 Million in Public Offering of Shares 31
Novacyt Raises USD0.2 Million in Public Offering of Shares 32
Novacyt Raises USD0.1 Million in Public Offering of Shares 33
Novacyt Raises USD0.2 Million in Public Offering of Shares 34
Novacyt to Raise USD1.5 Million in Private Placement of Shares 35
Novacyt Raises USD0.5 Million in Public Offering of Shares 36
Novacyt Raises USD0.1 Million in Public Offering of Shares 37
Novacyt Raises USD7.3 Million in Public Offering of Shares 38
Novacyt Raises USD0.1 Million in Public Offering of Shares 39
Novacyt Raises USD0.1 Million in Public Offering of Shares 40
Novacyt Raises USD2.2 Million in Second and Final Tranche of Private Placement of Shares 41
Novacyt Raises USD2.2 Million in First Tranche of Private Placement of Shares 42
Novacyt Raises USD2 Million in Public Offering of Shares 43
Novacyt Raises USD0.1 Million in Public Offering of Shares 44
Novacyt Raises USD2.16 Million in Private Placement of Shares 45
Novacyt to Raise USD3 Million in Private Placement of Shares 46
Novacyt Raises USD3.4 Million in IPO 47
Debt Offering 48
Novacyt Raises USD3.3 Million in Private Placement of 12.5% Bonds Due 2019 48
Novacyt Raises USD0.27 Million in First Tranche Private Placement of Bonds 49
Asset Transactions 50
Trinity Biotech Acquires Blood Bank Screening Business Of Lab 21 For US$7.5 Million 50
Lab21 Sells South Carolina Operations To Reedy Acquisitions 51
Acquisition 52
Novacyt Acquires PrimerDesign 52
Novacyt Completes Acquisition of Lab21, Medicine Diagnostics Company 53
Novacyt SA – Key Competitors 54
Novacyt SA – Key Employees 55
Novacyt SA – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 57
Financial Announcements 57
Sep 26, 2018: Novacyt half year 2018 results molecular product revenues up 18% to €3m gross margin increases to 64% 57
Aug 02, 2018: Novacyt half year revenue update 61
Apr 26, 2018: Novacyt Full Year 2017 Results 63
Jan 24, 2018: Novacyt Revenues Full Year 2017 68
Aug 16, 2017: Novacyt Half Year 2017 Results Consolidated sales growth +53% CER Group continues positive outlook for 2017 69
Jul 20, 2017: Novacyt Revenues Half Year 2017 73
Apr 27, 2017: Novacyt Full Year 2016 Results Deliver Double Digit Sales Growth 74
Jan 24, 2017: Novacyt Revenues Full Year 2016 77
Corporate Communications 79
Oct 03, 2017: Novacyt Strengthens Primerdesign Business With New Senior Hire 79
Other Significant Developments 80
Sep 13, 2018: Novacyt partners with Applied Microarrays in assay design 80
Mar 22, 2018: Novacyt Signs Assay Development Contract for Diagnosis of Respiratory Infections with GenePOC 81
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82

List of Tables
Novacyt SA, Medical Equipment, Key Facts, 2017 2
Novacyt SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Novacyt SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Novacyt SA, Medical Equipment Deals By Type, 2012 to YTD 2018 8
Novacyt SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Novacyt SA, Deals By Market, 2012 to YTD 2018 10
Novacyt SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
Lab21 Healthcare to Acquire Infectious Disease Business from Omega Diagnostics for up to USD2.8 Million 13
Novacyt Acquires Assets Of Centre de Competences International en Tele-Imagerie 14
Lab21 Raises US$7.7 Million In Venture Financing 15
Novacyt Raises US$2 Million In Venture Financing 16
Selah Genomics Acquires Lab21, Maker Of Nanotechnology-Enabled Products 17
Lab21 Enters Into Licensing Agreement With Cooperative Diagnostics 18
PrimerDesign Partners with Applied Microarrays 19
Novacyt Enters into Partnership with Cepheid 20
Novacyt Enters into Clinical Trial Agreement with St Stephen’s AIDS Trust 21
Lab21 Enters Into Agreement With IntegraGen To Develop Cancer Diagnostic 22
BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 23
Lab21 Enters Into Co-Development Agreement With Pharma Company 24
LAB21 Enters Into Co-Development Agreement With IVD Company For Aspergillus Molecular Assay 25
Novacyt Raises USD11.4 Million in Private Placement of Shares 26
Novacyt Raises USD3.35 Million in Public Offering of Shares 27
Novacyt Raises USD0.2 Million in Public Offering of Shares 28
Novacyt Raises USD2.9 Million in Public Offering of Shares 29
Novacyt Raises USD0.1 Million in Public Offering of Shares 30
Novacyt Raises USD0.1 Million in Public Offering of Shares 31
Novacyt Raises USD0.2 Million in Public Offering of Shares 32
Novacyt Raises USD0.1 Million in Public Offering of Shares 33
Novacyt Raises USD0.2 Million in Public Offering of Shares 34
Novacyt to Raise USD1.5 Million in Private Placement of Shares 35
Novacyt Raises USD0.5 Million in Public Offering of Shares 36
Novacyt Raises USD0.1 Million in Public Offering of Shares 37
Novacyt Raises USD7.3 Million in Public Offering of Shares 38
Novacyt Raises USD0.1 Million in Public Offering of Shares 39
Novacyt Raises USD0.1 Million in Public Offering of Shares 40
Novacyt Raises USD2.2 Million in Second and Final Tranche of Private Placement of Shares 41
Novacyt Raises USD2.2 Million in First Tranche of Private Placement of Shares 42
Novacyt Raises USD2 Million in Public Offering of Shares 43
Novacyt Raises USD0.1 Million in Public Offering of Shares 44
Novacyt Raises USD2.16 Million in Private Placement of Shares 45
Novacyt to Raise USD3 Million in Private Placement of Shares 46
Novacyt Raises USD3.4 Million in IPO 47
Novacyt Raises USD3.3 Million in Private Placement of 12.5% Bonds Due 2019 48
Novacyt Raises USD0.27 Million in First Tranche Private Placement of Bonds 49
Trinity Biotech Acquires Blood Bank Screening Business Of Lab 21 For US$7.5 Million 50
Lab21 Sells South Carolina Operations To Reedy Acquisitions 51
Novacyt Acquires PrimerDesign 52
Novacyt Completes Acquisition of Lab21, Medicine Diagnostics Company 53
Novacyt SA, Key Competitors 54
Novacyt SA, Key Employees 55
Novacyt SA, Subsidiaries 56

List of Figures
Novacyt SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Novacyt SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Novacyt SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Novacyt SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Novacyt SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Novacyt SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 8
Novacyt SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Novacyt SA, Medical Equipment, Deals by Market, 2012 to YTD 2018 10

★海外企業調査レポート[Novacyt SA (ALNOV):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Crocs Inc (CROX):企業の財務・戦略的SWOT分析
    Crocs Inc (CROX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Morinaga & Co., Ltd. (2201):企業の財務・戦略的SWOT分析
    Morinaga & Co., Ltd. (2201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Tetra Pak International SA:企業の戦略・SWOT・財務分析
    Tetra Pak International SA - Strategy, SWOT and Corporate Finance Report Summary Tetra Pak International SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Serina Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Serina Therapeutics Inc (Serina Therapeutics) is a pharmaceutical company that develops therapeutics for cancer, neurological diseases, pain and metabolic disorders. The company’s pipeline products include SER-214, SER-227, SER-228, SER-232, and other proprietary drugs. It uses proprietary t …
  • Heinzel Holding GmbH:企業の戦略的SWOT分析
    Heinzel Holding GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Taconic Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Taconic Biosciences Inc (Taconic), formerly Taconic Farms Inc is a research model provider that offers animal health models and laboratory services. The company’s products include taconic transgenic mouse models, emerging models, cryopreserved models, traditional models, diet induced obese, …
  • DSE, Inc.:企業の戦略・SWOT・財務分析
    DSE, Inc. - Strategy, SWOT and Corporate Finance Report Summary DSE, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • DiaCarta Inc-医療機器分野:企業M&A・提携分析
    Summary DiaCarta Inc (DiaCarta) develops and commercializes molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and also provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation de …
  • A. Menarini Industrie Farmaceutiche Riunite Srl:企業の戦略的SWOT分析
    A. Menarini Industrie Farmaceutiche Riunite Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Mabuhay Vinyl Corp (MVC):企業の財務・戦略的SWOT分析
    Mabuhay Vinyl Corp (MVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nokia Corporation:戦略・SWOT・企業財務分析
    Nokia Corporation - Strategy, SWOT and Corporate Finance Report Summary Nokia Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ClearFlow Inc-医療機器分野:企業M&A・提携分析
    Summary ClearFlow Inc (ClearFlow) is a medical device company that offers surgical equipment. The company designs, develops, manufactures and markets anti-clogging platform of surgical devices. Its products include gastrointestinal catheters, urinary catheters and wound drainage. ClearFlow’s product …
  • HomeWorks Tri-County Electric Cooperative Inc:企業の発電所・SWOT分析2018
    HomeWorks Tri-County Electric Cooperative Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, in …
  • CoreSite Realty Corp (COR):企業の財務・戦略的SWOT分析
    CoreSite Realty Corp (COR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Protalix BioTherapeutics Inc (PLX):企業の財務・戦略的SWOT分析
    Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Hill-Rom Holdings Inc (HRC)-医療機器分野:企業M&A・提携分析
    Summary Hill-Rom Holdings Inc (Hill-Rom) is a medical technology company that offers patient support systems, surgical solutions and other front line care products. The company’s major products and services include patient care systems; safe mobility and handling solutions; non-invasive therapeutic …
  • Titan Company Ltd (TITAN):企業の財務・戦略的SWOT分析
    Summary Titan Company Ltd (Titan) is a retailing company. Its product portfolio includes eyewear, watches and accessories; jewelry; and fashion accessories. The company offers jewelry products comprising of pendant, chain, gold coin, earrings, finger ring and neckwear. Titan offers eyewear products …
  • Nippon Soda Co., Ltd.:企業の戦略・SWOT・財務情報
    Nippon Soda Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Soda Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • QIAGEN N.V.:企業の戦略・SWOT・財務情報
    QIAGEN N.V. - Strategy, SWOT and Corporate Finance Report Summary QIAGEN N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Kawasaki Kisen Kaisha, Ltd. (9107)-石油・ガス分野:企業M&A・提携分析
    Summary Kawasaki Kisen Kaisha, Ltd. (K Line) is a global logistics company. K Line’s business lines include land transportation, air transportation, marine transportation, and harbor transportation. It owns and operates dry bulk carriers, LNG carriers, tankers, car carriers and containerships. The c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆